Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Here are five bourbons, top picks at the SFWSC, that you must try. All five bourbons are finalists for the coveted prize of ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

The publication reports results from the 96-week SYMMETRY study evaluating the efficacy and safety of Akero's lead FGF21 ...

Gyre Therapeutics ("Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 ...

“It is an absolute phenom for us to be able to present to you now our teenage aspirations in this song”: Joe Satriani and ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

Source: Malaria cases in Mash West increase – herald Conrad Mupesa-Mashonaland West Bureau MASHONALAND West Province is ...

Mashle: Magic and Muscles captivates audiences with its tale of Mash Burnedead, a magicless youth challenging a ...